Related Experiment Videos
[Neonatal screening for cystic fibrosis]
J J Tellería Orriols1, M J Alonso Ramos, J A Garrote Adrados
1Area de Pediatría. Instituto de Biología y Genética Molecular (IBGM). Universidad de Valladolid/CSIC. España.
Anales Espanoles De Pediatria
|July 26, 2002
Summary
Neonatal screening for cystic fibrosis (CF) using immunoreactive trypsinogen (IRT) and genetic testing is efficient. This two-stage method achieves 98.5% sensitivity in detecting CF in newborns.
Area of Science:
- Biochemistry
- Genetics
- Pediatrics
Context:
- Neonatal screening programs are crucial for early detection of genetic disorders.
- Cystic Fibrosis (CF) diagnosis relies on biochemical and genetic markers.
- The Guthrie spot blood test is a common method for newborn screening.
Purpose:
- To evaluate the efficiency of a two-stage neonatal screening protocol for Cystic Fibrosis (CF) in Castille and Leon, Spain.
- To assess the sensitivity and reliability of using immunoreactive trypsinogen (IRT) levels and CFTR gene mutation analysis.
- To determine the prevalence of CF and healthy carriers within the screened population.
Summary:
- A total of 36,086 newborns were screened using a two-stage approach: IRT quantification followed by CFTR gene analysis for elevated IRT levels.
- The screening identified 8 cases of CF and 11 healthy carriers with one CFTR mutation, demonstrating a sensitivity of 98.5%.
- No false negatives were detected during the study period, indicating a high degree of accuracy.
Impact:
- The established two-stage screening method meets essential criteria for neonatal screening programs.
- The findings support the adaptability of this screening model for other regions.
- Optimization of genetic screening is recommended to identify region-specific CFTR mutations for improved diagnostic yield.